Artykuły w czasopismach na temat „Vaccins ADN”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Vaccins ADN”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Ladenheim, Ruth. "Les vaccins à ADN nu". Biofutur 1995, nr 145 (maj 1995): 14. http://dx.doi.org/10.1016/0294-3506(95)80125-1.
Pełny tekst źródłaPitard, Bruno. "Nanotaxi® pour les vaccins ARN et ADN". médecine/sciences 35, nr 10 (październik 2019): 749–52. http://dx.doi.org/10.1051/medsci/2019143.
Pełny tekst źródłaQUENTEL, C., M. BREMONT i H. POULIQUEN. "La vaccination chez les poissons d’élevage". INRAE Productions Animales 20, nr 3 (7.09.2007): 233–38. http://dx.doi.org/10.20870/productions-animales.2007.20.3.3463.
Pełny tekst źródłaParis, Robert, Robert A. Kuschner, Leonard Binn, Stephen J. Thomas, Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Robert T. Bailer, Nancy Sullivan i Richard A. Koup. "Adenovirus Type 4 and 7 Vaccination or Adenovirus Type 4 Respiratory Infection Elicits Minimal Cross-Reactive Antibody Responses to Nonhuman Adenovirus Vaccine Vectors". Clinical and Vaccine Immunology 21, nr 5 (12.03.2014): 783–86. http://dx.doi.org/10.1128/cvi.00011-14.
Pełny tekst źródłaHarro, Clayton, Xiao Sun, Jon E. Stek, Randi Y. Leavitt, Devan V. Mehrotra, Fubao Wang, Andrew J. Bett i in. "Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults". Clinical and Vaccine Immunology 16, nr 9 (15.07.2009): 1285–92. http://dx.doi.org/10.1128/cvi.00144-09.
Pełny tekst źródłaBeaty, Shannon, Natalie Collins, Nicos Karasavvas, Robert Kuschner, Jun Hang, Anima Adhikari, Irina Maljkovic Berry i in. "A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults". Vaccines 11, nr 6 (12.06.2023): 1091. http://dx.doi.org/10.3390/vaccines11061091.
Pełny tekst źródła邱南昌, 邱南昌, i 張濱璿 Nan-Chang Chiu. "臺灣預防接種受害救濟制度與COVID-19疫苗". 月旦醫事法報告 67, nr 67 (maj 2022): 050–61. http://dx.doi.org/10.53106/241553062022050067004.
Pełny tekst źródłaHalstead, Scott B., i Leah Katzelnick. "COVID-19 Vaccines: Should We Fear ADE?" Journal of Infectious Diseases 222, nr 12 (12.08.2020): 1946–50. http://dx.doi.org/10.1093/infdis/jiaa518.
Pełny tekst źródłaYılmaz, Engin. "Aşı Teknolojisinde Yeni Umutlar: mRNA Aşıları". Mikrobiyoloji Bulteni 55, nr 2 (19.04.2021): 265–84. http://dx.doi.org/10.5578/mb.20219912.
Pełny tekst źródłaAppledorn, Daniel M., Yasser A. Aldhamen, Sarah Godbehere, Sergey S. Seregin i Andrea Amalfitano. "Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity". Clinical and Vaccine Immunology 18, nr 1 (17.11.2010): 150–60. http://dx.doi.org/10.1128/cvi.00341-10.
Pełny tekst źródłaGuzmán-Martínez, Oscar, Kathia Guardado, Elsa Ladrón de Guevara, Saturnino Navarro, Crescencio Hernández, Roberto Zenteno-Cuevas i Hilda Montero. "IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population". Vaccines 9, nr 9 (8.09.2021): 999. http://dx.doi.org/10.3390/vaccines9090999.
Pełny tekst źródłaTang, Jinyi, Cong Zeng, Thomas M. Cox, Chaofan Li, Young Min Son, In Su Cheon, Supriya Behl i in. "Respiratory humoral and cellular immune responses following COVID-19 mRNA vaccination". Journal of Immunology 208, nr 1_Supplement (1.05.2022): 65.22. http://dx.doi.org/10.4049/jimmunol.208.supp.65.22.
Pełny tekst źródłaThiele, Sonja, Aljona Borschewski, Judit Küchler, Marc Bieberbach, Sebastian Voigt i Bernhard Ehlers. "Molecular Analysis of Varicella Vaccines and Varicella-Zoster Virus from Vaccine-Related Skin Lesions". Clinical and Vaccine Immunology 18, nr 7 (11.05.2011): 1058–66. http://dx.doi.org/10.1128/cvi.05021-11.
Pełny tekst źródłaBroderick, Michael P., Sandra Romero-Steiner, Gowrisankar Rajam, Scott E. Johnson, Andrea Milton, Ellie Kim, Lisa J. Choi i in. "Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone". Clinical and Vaccine Immunology 23, nr 8 (8.06.2016): 672–80. http://dx.doi.org/10.1128/cvi.00267-16.
Pełny tekst źródłaBraucher, Douglas R., Jamie N. Henningson, Crystal L. Loving, Amy L. Vincent, Eun Kim, Julia Steitz, Andrea A. Gambotto i Marcus E. Kehrli. "Intranasal Vaccination with Replication-Defective Adenovirus Type 5 Encoding Influenza Virus Hemagglutinin Elicits Protective Immunity to Homologous Challenge and Partial Protection to Heterologous Challenge in Pigs". Clinical and Vaccine Immunology 19, nr 11 (29.08.2012): 1722–29. http://dx.doi.org/10.1128/cvi.00315-12.
Pełny tekst źródłaWang, Anqi. "Advantages And Disadvantages of Different COVID-19 Vaccines". Highlights in Science, Engineering and Technology 45 (18.04.2023): 319–24. http://dx.doi.org/10.54097/hset.v45i.7483.
Pełny tekst źródłaMuñoz-Valle, José Francisco, Gabriela Athziri Sánchez-Zuno, Mónica Guadalupe Matuz-Flores, Cristian Oswaldo Hernández-Ramírez, Saúl Alberto Díaz-Pérez, Christian Johana Baños-Hernández, Francisco Javier Turrubiates-Hernández, Alejandra Natali Vega-Magaña i Jorge Hernández-Bello. "Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study". Vaccines 10, nr 3 (5.03.2022): 400. http://dx.doi.org/10.3390/vaccines10030400.
Pełny tekst źródłaChondronasiou, Dafni, Tracy-Jane Eisden, Anita Stam, Qiana Matthews, Mert Icyuz, Erik Hooijberg, Igor Dmitriev, David Curiel, Tanja de Gruijl i Rieneke van de Ven. "Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs". Vaccines 6, nr 3 (18.07.2018): 42. http://dx.doi.org/10.3390/vaccines6030042.
Pełny tekst źródłaCassier, Maurice. "Producing, Controlling, and Stabilizing Pasteur's Anthrax Vaccine: Creating a New Industry and a Health Market". Science in Context 21, nr 2 (czerwiec 2008): 253–78. http://dx.doi.org/10.1017/s0269889708001713.
Pełny tekst źródłaSun, Haiyan, Dhiraj Acharya, Amber M. Paul, Huafang Lai, Junyun He, Fengwei Bai i Qiang Chen. "Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus". Vaccines 11, nr 2 (17.01.2023): 197. http://dx.doi.org/10.3390/vaccines11020197.
Pełny tekst źródłaDeng, Sheng-Qun, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang i Hong-Juan Peng. "A Review on Dengue Vaccine Development". Vaccines 8, nr 1 (2.02.2020): 63. http://dx.doi.org/10.3390/vaccines8010063.
Pełny tekst źródłaMcFarland, Elizabeth J., Ruth A. Karron, Petronella Muresan, Coleen K. Cunningham, Charlotte Perlowski, Jennifer Libous, Jennifer Oliva i in. "Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children". Journal of Infectious Diseases 221, nr 12 (1.02.2020): 2050–59. http://dx.doi.org/10.1093/infdis/jiaa049.
Pełny tekst źródłaWilson, Nancy A., Brandon F. Keele, Jason S. Reed, Shari M. Piaskowski, Caitlin E. MacNair, Andrew J. Bett, Xiaoping Liang i in. "Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge". Journal of Virology 83, nr 13 (29.04.2009): 6508–21. http://dx.doi.org/10.1128/jvi.00272-09.
Pełny tekst źródłaWhelan, Allison M. "Lowering the Age of Consent: Pushing Back against the Anti-Vaccine Movement". Journal of Law, Medicine & Ethics 44, nr 3 (2016): 462–73. http://dx.doi.org/10.1177/1073110516667942.
Pełny tekst źródłaAli, Muhammad Zahid, Yousra Anwar, Adil Abbas, Noor Ul Ain, Zainab Khalid, Arooj Sattar, Muhammad Usman, Arzoo Nazir i Shah Zeb. "Recent Advances in Vaccine Technology for Viral Infection Management: A Spotlight on Next-Generation Vaccines and Nucleic Acid-Based Platforms". Pakistan Journal of Medical and Health Sciences 17, nr 5 (23.06.2023): 261–66. http://dx.doi.org/10.53350/pjmhs2023175261.
Pełny tekst źródłaCrum, Tommie, Kirsten Mooney i Birendra R. Tiwari. "Current situation of vaccine injury compensation program and a future perspective in light of COVID-19 and emerging viral diseases". F1000Research 10 (7.12.2021): 652. http://dx.doi.org/10.12688/f1000research.51160.2.
Pełny tekst źródłaCrum, Tommie, Kirsten Mooney i Birendra R. Tiwari. "Current situation of vaccine injury compensation program and a future perspective in light of COVID-19 and emerging viral diseases". F1000Research 10 (26.07.2021): 652. http://dx.doi.org/10.12688/f1000research.51160.1.
Pełny tekst źródłaMatsegora, N. А., i A. V. Kaprosh. "Current state of developments and research of new candidate vaccines against tuberculosis (literature review)". Tuberculosis, Lung Diseases, HIV Infection, nr 2 (17.06.2022): 48–57. http://dx.doi.org/10.30978/tb-2022-2-48.
Pełny tekst źródłaLiang, Xiaoping, Danilo R. Casimiro, William A. Schleif, Fubao Wang, Mary-Ellen Davies, Zhi-Qiang Zhang, Tong-Ming Fu i in. "Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys". Journal of Virology 79, nr 19 (1.10.2005): 12321–31. http://dx.doi.org/10.1128/jvi.79.19.12321-12331.2005.
Pełny tekst źródłaLau, Chin Shern, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu i Tar Choon Aw. "Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore". Antibodies 11, nr 2 (27.05.2022): 38. http://dx.doi.org/10.3390/antib11020038.
Pełny tekst źródłaSteinhoff, Mark C., George F. Reed, Michael D. Decker, Kathryn M. Edwards, Janet A. Englund, Michael E. Pichichero, Margaret B. Rennels, Edwin L. Anderson, Maria A. Deloria i Bruce D. Meade. "A Randomized Comparison of Reactogenicity and Immunogenicity of Two Whole-Cell Pertussis Vaccines". Pediatrics 96, nr 3 (1.09.1995): 567–70. http://dx.doi.org/10.1542/peds.96.3.567.
Pełny tekst źródłaKim, Ji Yeun, So Yun Lim, Soonju Park, Ji-Soo Kwon, Seongman Bae, Ji Young Park, Hye Hee Cha i in. "Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period". Journal of Infectious Diseases 225, nr 5 (25.11.2021): 777–84. http://dx.doi.org/10.1093/infdis/jiab579.
Pełny tekst źródłaCasimiro, Danilo R., Aimin Tang, Ling Chen, Tong-Ming Fu, Robert K. Evans, Mary-Ellen Davies, Daniel C. Freed i in. "Vaccine-Induced Immunity in Baboons by Using DNA and Replication-Incompetent Adenovirus Type 5 Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene". Journal of Virology 77, nr 13 (1.07.2003): 7663–68. http://dx.doi.org/10.1128/jvi.77.13.7663-7668.2003.
Pełny tekst źródłaIyasu Angani, Dereja. "Veterinary vaccine development: The helical project". Insights in Veterinary Science 4, nr 1 (28.08.2020): 042–47. http://dx.doi.org/10.29328/journal.ivs.1001025.
Pełny tekst źródłaKang, Chang-Yuil, Soojeong Chang, Kwang-Soo Shin, In Kyung Jung, Hyemin Park, Jonghan Oh, Seowoo Park, Jieun Shin i Jong Heon Kim. "Development of broadly protective COVID-19 vaccine against up-to-date variants based on adenovirus type 5/35 vector platform." Journal of Immunology 210, nr 1_Supplement (1.05.2023): 159.06. http://dx.doi.org/10.4049/jimmunol.210.supp.159.06.
Pełny tekst źródłaKawile, Leo, Keli Fisher i Mia Noergaard. "An Exploration of the Relationship Between Vaccine Knowledge and Vaccine Willingness". Psi Beta Research Journal - Brief Reports 3, nr 1 (12.10.2023): 56–60. http://dx.doi.org/10.54581/luzr1510.
Pełny tekst źródłaCamacho, Luiz Antonio Bastos, Marcos da Silva Freire, Maria da Luz Fernandes Leal, Savitri Gomes de Aguiar, Jussara Pereira do Nascimento, Takumi Iguchi, José de Azevedo Lozana i Roberto Henrique Guedes Farias. "Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial". Revista de Saúde Pública 38, nr 5 (październik 2004): 671–78. http://dx.doi.org/10.1590/s0034-89102004000500009.
Pełny tekst źródłaBalatif, Ridwan, Fadlan Hafizh Harahap i Isni Dhiyah Almira. "Recent Development on HIV Variants and HIV Vaccine". Cermin Dunia Kedokteran 49, nr 12 (1.12.2022): 687–92. http://dx.doi.org/10.55175/cdk.v49i12.328.
Pełny tekst źródłaKamboj, Sakshi, Siya Srivastava, Sana Siddiqui i Rohit Singh. "A WEB-BASED CROSS-SECTIONAL STUDY AMONG INDIANS REVEALS A WILLINGNESS SHIFT REGARDING COVID-19 VACCINE UPTAKE AFTER THE SECOND WAVE". Journal of Experimental Biology and Agricultural Sciences 9, nr 5 (30.10.2021): 647–56. http://dx.doi.org/10.18006/2021.9(5).647.656.
Pełny tekst źródłaWang, Meicheng. "Dengue virus and vaccines: A review". Theoretical and Natural Science 15, nr 1 (4.12.2023): 292–98. http://dx.doi.org/10.54254/2753-8818/15/20240502.
Pełny tekst źródłaAuclair, Sarah, Lynn Soong i Haitao Hu. "Differential T follicular helper cell responses induced by candidate HIV vaccine strategies utilizing ALVAC versus Ad5 vectors". Journal of Immunology 200, nr 1_Supplement (1.05.2018): 125.22. http://dx.doi.org/10.4049/jimmunol.200.supp.125.22.
Pełny tekst źródłaKotaki, Tomohiro, Yurie Nagai, Atsushi Yamanaka, Eiji Konishi i Masanori Kameoka. "Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection". Vaccines 10, nr 9 (28.08.2022): 1411. http://dx.doi.org/10.3390/vaccines10091411.
Pełny tekst źródłaBarouch, Dan H., Paul F. McKay, Shawn M. Sumida, Sampa Santra, Shawn S. Jackson, Darci A. Gorgone, Michelle A. Lifton i in. "Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines". Journal of Virology 77, nr 16 (15.08.2003): 8729–35. http://dx.doi.org/10.1128/jvi.77.16.8729-8735.2003.
Pełny tekst źródłaTogoo, Khongorzul, Burenjargal Batmunkh, Nomin-Erdene Tsogtbayar, Ulziisaikhan Batmunkh, Enkhtuya Selenge, Khuselt-Od Togtokhbaatar, Gantuya Boldbaatar, Davaalkham Jagdagsuren, Batbaatar Gunchin i Tsogtsaikhan Sandag. "Antibody response of Comirnaty vaccine in different immunocompromised groups during the COVID-19 pandemic". Journal of Immunology 210, nr 1_Supplement (1.05.2023): 252.13. http://dx.doi.org/10.4049/jimmunol.210.supp.252.13.
Pełny tekst źródłaKrasnopolsky, Yu. "BIOTECHNOLOGICAL RESEARCH IN THE CREATION AND PRODUCTION OF ANTIRABIC VACCINES". Biotechnologia Acta 14, nr 4 (sierpień 2021): 28–37. http://dx.doi.org/10.15407/biotech14.04.028.
Pełny tekst źródłaI, Rabiu. "COVID-19 Vaccine Hesitancy in Africa and Asian Continent: A Comparative Study Between Nigeria and Nepal". Vaccines & Vaccination Open Access 8, nr 2 (4.08.2023): 1–8. http://dx.doi.org/10.23880/vvoa-16000166.
Pełny tekst źródłaCamara, Aichetou, Anaïs Razurel, Christelle Moreau, Thérésa Kwon, Marion Caseris, Olivier Bourdon i Sonia Prot-Labarthe. "P44 Vaccine in pediatric chronic kidney disease (CKD) and hemodialysis". Archives of Disease in Childhood 105, nr 9 (19.08.2020): e29.2-e30. http://dx.doi.org/10.1136/archdischild-2020-nppg.53.
Pełny tekst źródłaTapia-Calle, Gabriela, Philip A. Born, Georgia Koutsoumpli, Martin Ignacio Gonzalez-Rodriguez, Wouter L. J. Hinrichs i Anke L. W. Huckriede. "A PBMC-Based System to Assess Human T Cell Responses to Influenza Vaccine Candidates In Vitro". Vaccines 7, nr 4 (13.11.2019): 181. http://dx.doi.org/10.3390/vaccines7040181.
Pełny tekst źródłaWei, Yunhua, Yan Wang, Lin Liu, Yan Zha, Yuqi Yang, Yuanlin Wang, Neil Roberts i Yaying Li. "Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China". Vaccines 10, nr 9 (2.09.2022): 1449. http://dx.doi.org/10.3390/vaccines10091449.
Pełny tekst źródłaGbaj, Abdul. "Mixing of Sputnik V and AstraZeneca COVID-19 vaccines". Clinical Research Notes 2, nr 1 (6.09.2021): 01–03. http://dx.doi.org/10.31579/2690-8816/034.
Pełny tekst źródła